Purple Biotech Drug Patent Portfolio
Purple Biotech owns 1 orange book drug protected by 5 US patents Given below is the list of Purple Biotech's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10350171 | Celecoxib and amlodipine formulation and method of making the same | 14 Jun, 2038 | Active |
| US10925835 | Celecoxib and amlodipine formulation and method of making the same | 14 Jun, 2038 | Active |
| US10945960 | Celecoxib and amlodipine formulation and method of making the same | 14 Jun, 2038 | Active |
| US9408837 | Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs | 28 Feb, 2030 | Active |
| US9662315 | Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs | 22 May, 2029 | Active |
Latest Legal Activities on Purple Biotech's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Purple Biotech.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 16 Jan, 2023 | US10350171 |
|
Recordation of Patent Grant Mailed
Critical
| 16 Mar, 2021 | US10945960 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 16 Mar, 2021 | US10945960 |
|
Issue Notification Mailed
Critical
| 24 Feb, 2021 | US10945960 |
|
Recordation of Patent Grant Mailed
Critical
| 23 Feb, 2021 | US10925835 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 23 Feb, 2021 | US10925835 |
| Dispatch to FDC | 10 Feb, 2021 | US10945960 |
|
Application Is Considered Ready for Issue
Critical
| 10 Feb, 2021 | US10945960 |
|
Issue Fee Payment Received
Critical
| 08 Feb, 2021 | US10945960 |
|
Issue Fee Payment Verified
Critical
| 08 Feb, 2021 | US10945960 |
|
Mail Notice of Allowance
Critical
| 03 Feb, 2021 | US10945960 |
|
Issue Notification Mailed
Critical
| 03 Feb, 2021 | US10925835 |
|
Notice of Allowance Data Verification Completed
Critical
| 31 Jan, 2021 | US10945960 |
| Dispatch to FDC | 28 Jan, 2021 | US10925835 |
|
Application Is Considered Ready for Issue
Critical
| 20 Jan, 2021 | US10925835 |
Purple Biotech's Family Patents
Purple Biotech Drug List
Given below is the complete list of Purple Biotech's drugs and the patents protecting them.
1. Consensi
Consensi is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10350171 | Celecoxib and amlodipine formulation and method of making the same |
14 Jun, 2038
(13 years from now)
| Active |
| US10925835 | Celecoxib and amlodipine formulation and method of making the same |
14 Jun, 2038
(13 years from now)
| Active |
| US10945960 | Celecoxib and amlodipine formulation and method of making the same |
14 Jun, 2038
(13 years from now)
| Active |
| US9408837 | Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs |
28 Feb, 2030
(5 years from now)
| Active |
| US9662315 | Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs |
22 May, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Consensi's drug page